Esperion Therapeutics (ESPR) EBITDA (2012 - 2026)

Esperion Therapeutics has reported EBITDA for 15 years, with the latest figure at -$25.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 37.72% year-over-year to -$25.2 million; the trailing twelve-month figure through Mar 2026 stood at -$7.4 million (up 95.16% YoY), and the FY2025 full-year result was -$22.7 million, up 56.17% from the prior year.
• EBITDA for Q1 2026 stood at -$25.2 million, down from $61.8 million in the prior quarter.
• The five-year high for EBITDA was $61.8 million in Q4 2025, with the low at -$66.4 million in Q2 2022.
• Historically, EBITDA has averaged -$31.9 million across 5 years, with a median of -$41.2 million in 2023.
• The largest YoY upside for EBITDA was 390.04% in 2025 against a maximum downside of 166.3% in 2025.
• Esperion Therapeutics' EBITDA stood at -$55.4 million in 2022, then slipped by 1.71% to -$56.3 million in 2023, then surged by 62.16% to -$21.3 million in 2024, then surged by 390.04% to $61.8 million in 2025, then tumbled by 140.75% to -$25.2 million in 2026.
• The last three EBITDA figures came in at -$25.2 million (Q1 2026), $61.8 million (Q4 2025), and -$31.3 million (Q3 2025), per Business Quant data.